Influenza Market Analysis Report 2025 with Forecast to 2029: Government Support and Funding for Novel Therapies and Diagnosis Fueling Developments
Global Influenza Market to Hit USD 12.8 Billion by 2029: A Comprehensive AnalysisThe global influenza market, valued at USD 9 billion in 2024, is anticipated to grow at a CAGR of 7.2%, reaching USD 12.8 billion by 2029. This growth is driven by the vaccine segment, the most effective preventive measure against influenza's severe effects. The report offers a thorough examination of market trends, including vaccines, diagnostics, and therapeutics, with insights into regional dynamics and competitive landscapes. Key players such as Danaher Corp., Sanofi, and Abbott are highlighted, alongside detailed analyses using Porter's Five Forces and PESTLE models. SEO keywords include global influenza market, influenza vaccines, diagnostics, and market growth.
Influenza Market
Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "Influenza Market 2025" report has been added to ResearchAndMarkets.com's offering.The Influenza Market was valued at USD 9 Billion in 2024, and is projected to reach USD 12.8 Billion by 2029, rising at a CAGR of 7.2%. The vaccines segment dominated the global influenza market in 2023. Because influenza vaccines are the most effective method for lowering the risk of contracting influenza and suffering its subsequent effects, the market for this segment is growing. Influenza comes in four varieties: A, B, C and D. Seasonal epidemics are caused by the infectious influenza A and B viruses.
Most people recover from fever and other symptoms within a week without medical intervention. Nevertheless, influenza can result in fatalities or severe illness, particularly in high-risk populations. Seasonal influenza spreads quickly and easily in crowded places like schools and nursing homes, so receiving a vaccination as soon as possible is critical. Based on vaccine type, the segment is further subdivided into inactivated and liveattenuated vaccines.The market for influenza diagnostics has been segmented into rapid tests and conventional lab tests based on diagnostic type. Increased R&D efforts are being made to detect and diagnose influenza more accurately due to its increasing global prevalence. Research is focusing on developing quicker and more precise diagnostic tools for influenza viruses, which will expand the market.Antiviral drugs approved for influenza treatments are discussed in the therapeutic segment. These medications may lessen the likelihood of complications, lessen the severity of symptoms and shorten the course of the illness. These drugs include oseltamivir (Tamiflu), zanamivir (Relenza), peramivir (Rapivab) and baloxavir marboxil (Xofluza).Report ScopeThis report presents qualitative and quantitative data on the current dynamics impacting the global influenza market. It examines the history of various flu pandemics, disease burden and vaccine coverage in several countries. The report thoroughly evaluates the market for influenza vaccines, therapeutics and diagnostics.Analyses of the most popular products, clinical trials, new product approvals and emerging technologies are also included in the report. The demographics of the major regions - North America, Europe and Asia-Pacific - and their growth prospects are summarized. The profiles of leading companies and the strategies of international businesses involved in the influenza sector are also discussed.The market size for influenza is categorized into three product segments: vaccines, therapeutics and diagnostics. Vaccines are further segmented into inactivated vaccines and live-attenuated vaccines. Diagnostics are divided into rapid and conventional lab tests. Additional growth potential and forecast data are addressed for the influenza market in each product segment for every region.For market estimates, data are provided for 2023 as the base year, 2024 as the estimated year and forecast from 2025 through 2029.The report includes:
55 data tables and 70 additional tables
An updated overview and in-depth analysis of the global influenza market
Analyses of the global market trends, with sales data from 2021-2024, and projections of compound annual growth rates (CAGRs) through 2029
Estimates of the actual market size and revenue forecasts, and a corresponding market share analysis by product segment, and region
Discussion of the role of major vaccine providers and companion products approved for a wide variety of influenza testing platforms, including adenovirus, SARS, parainfluenza, coronavirus and human metapneumovirus (hMPV)
Analysis of the market opportunities through the Porter's Five Forces model and PESTLE analysis, taking into consideration the prevailing micro- and macro environmental factors
Insight into the influenza industry structure, government regulations, and key development issues
Analysis of the key patent grants and IP aspects
A discussion of the industry's ESG challenges and practices of the industry
Analysis of the competitive landscape, featuring the leading participants, their current market rankings, and their market shares
Profiles of the leading companies, including Danaher Corp., Sanofi, CSL, La Roche Ltd., and Abbott
Key Attributes:
Report Attribute
Details
No. of Pages
188
Forecast Period
2024 - 2029
Estimated Market Value (USD) in 2024
$9 Billion
Forecasted Market Value (USD) by 2029
$12.8 Billion
Compound Annual Growth Rate
7.2%
Regions Covered
Global
Key Topics Covered: Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
Pandemic Scenario
Porter's Five Forces Analysis in the Influenza Vaccines Market
Supply Chain Analysis
Vaccine Development
Vaccine Manufacturing
Storage and Inventory Management
Distribution
Administration and Immunization
Macroeconomic Factors Analysis
Impact of U.S.-China Trade War
Global Economic Growth
Demographic Trends
Public Health Crises and Pandemics
Chapter 3 Market Dynamics
Market Dynamics
Key Takeaways
Market Drivers
Development of Rapid Tests and Molecular Technologies
Government Support and Funding for Novel Therapies and Diagnosis
Rising Public Awareness About Flu Vaccines
Market Restraints
Therapeutic Market Dominated by Limited Suppliers
High Cost Associated with Storage and Supply of Flu Vaccines
Market Opportunities
Robust Pipeline of Influenza Vaccines
Demand for Improved Prevention, Treatment and Vaccine Accessibility
Chapter 4 Regulatory Landscape
Overview
Regulatory Aspects of Influenza Vaccines
Use of Trivalent Influenza Vaccines for the 2024-2025 U.S. Influenza Season
Influenza Vaccines Approved by EMA
Regulatory Scenario of Influenza Drugs
Approval Process of Influenza Detection Kit
Sensitivity
Specificity
Chapter 5 Emerging Trends and Pipeline Analysis
Overview
Advance in Influenza Diagnosis
SHINE Technology
Electrochemical Biosensors
Wearable Lab-on-a-Chip Devices
Quantum Dots and Fluorescent Nanoparticles
Role of AI in Influenza Diagnosis
Emerging Technologies in Influenza Vaccines
Universal Influenza Vaccine
mRNA-based Influenza Vaccines
Nanotechnology-based Vaccines
Patch-based Vaccines
Advances in Influenza Therapeutics
Nanoparticle-based Therapies
Potential Drug Agents in Clinical Trials
Patent Analysis
Key Takeaways
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Global Influenza Market by Product Segment
Influenza Diagnostics
Influenza Vaccines
Influenza Therapeutics
Geographic Breakdown
Key Takeaways
North America
Europe
Asia-Pacific
Rest of World
Chapter 7 Competitive Intelligence
Company Share Analysis of the Influenza Vaccines Market
Company Share Analysis of Influenza Diagnostics Market
Company Share Analysis of Influenza Therapeutics Market
Venture Fundings and Investments Landscape
Key Developments in Market
Chapter 8 Sustainability in Influenza Market: ESG Perspective
Overview
ESG Risk Ratings
Conclusion
Chapter 9 AppendixCompanies Featured
Abbott
AstraZeneca
BD
Biocryst Pharmaceuticals Inc.
CSL
Daiichi Sankyo Co. Ltd.
Danaher Corp.
F. Hoffmann-La Roche Ltd.
GSK PLC
Hologic Inc.
Quidelortho Corp.
Sanofi
Sekisui Diagnostics
Thermo Fisher Scientific Inc.
Viatris Inc.
For more information about this report visit https://www.researchandmarkets.com/r/wdn3a2
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Influenza Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Panhandle's First State Psychiatric Hospital Breaks Ground
Governor Greg Abbott announced that construction is officially underway on a new state-of-the-art mental health hospital, a modern psychiatric facility in North Texas. The $159 million project in Amarillo will bring much-needed inpatient mental health services to the 26-county Panhandle area for the first time in state history. The 75-bed hospital, funded by the Texas Legislature and spearheaded by the Texas Health and Human Services Commission (HHSC), is expected to be finished in 2027. At 164,475 square feet, it is designed to meet modern standards in psychiatric care and will be able to serve adults requiring severe inpatient treatment for psychiatric problems and other ailments. 'Texas is delivering on its promise to expand healthcare to rural communities across our great state,' Abbott said in a June 10 press release announcing the groundbreaking. 'This Panhandle State Hospital – the first state-operated facility in the region – will provide Texans greater access to mental health professionals and high-quality care close to home. I thank the Texas Legislature and the Texas Health and Human Services Commission for their work to increase access to mental healthcare for Texans in every corner of our state,' the governor added. The new facility will include 'communal activity spaces' and outdoor courtyards to promote recovery and social engagement for psychiatric patients. According to Abbott's office, the hospital's modern design is part of a broader strategy to integrate new evidence-based practices and layouts into mental health facilities. Cecile Erwin Young, HHSC's executive commissioner, talked about the importance of providing quality care to certain previously underserved communities across Texas. 'Texans are better served when they have access to healthcare closer to home, and that is why state leaders and HHSC have invested in facilities like the Panhandle State Hospital,' Young said. The Amarillo construction project is part of a sweeping overhaul of the state's mental health infrastructure. Since 2017, the Abbott administration and Texas lawmakers have allocated over $2.5 billion to modernize and expand the state's psychiatric care system, including renovating, replacing, or constructing hospitals across the state. The HHSC currently oversees nine different hospitals and one inpatient youth treatment center. These facilities provide 24/7 care for residents struggling with severe mental illness, including those found incompetent to stand trial in the legal system, or deemed a danger to themselves or others. With rural healthcare access a growing concern across the state, as previously reported on by The Dallas Express, the new hospital will be a big milestone in addressing mental health disparities across Texas. HHSC's official webpage has construction renderings of the new facility and updates on the project's progress. 'When completed, this hospital will offer hope and healing to some of the most vulnerable people in the Panhandle,' Young added.
Yahoo
9 hours ago
- Yahoo
Abbott Laboratories (NYSE:ABT) Partners With Tandem To Develop Dual Sensor Diabetes Solutions
Tandem Diabetes Care, Inc. recently announced a significant collaboration with Abbott Laboratories to integrate Abbott's upcoming dual glucose-ketone sensor with Tandem's insulin delivery systems. This and other collaborations, such as the agreement with Sequel Med Tech, align with Abbott's strategic focus on enhancing diabetes care. Abbott's shares rose 3% over the last quarter, aligning closely with broader market trends, which advanced 13% over the past year. The company's robust product approvals and partnerships, alongside positive market sentiment, likely reinforced investor confidence in Abbott's growth trajectory amid generally favorable market conditions. You should learn about the 1 possible red flag we've spotted with Abbott Laboratories. Find companies with promising cash flow potential yet trading below their fair value. The recent collaboration between Tandem Diabetes Care, Inc. and Abbott Laboratories to integrate Abbott's dual glucose-ketone sensor has the potential to enhance Abbott's market positioning in diabetes care. This partnership, along with other strategic agreements, could support revenue growth in Abbott's Diabetes Care segment, though challenges such as tariffs and VBP program impacts in China remain. Abbott's five-year total return, including share price and dividends, stands at 63.31%, showcasing strong longer-term performance, despite some earnings forecast pressure. In the past year, Abbott's shares have risen above the US Medical Equipment industry, which saw a return of 8.2%. This outperformance over a shorter time horizon indicates that investor confidence remains buoyant. However, the expectation of declining earnings over the next three years, with a 10.1% decrease per year, highlights forecast challenges. This contrasts with a forecasted revenue growth of 6.9% annually, which is slower than the broader US market growth rate of 8.6% per year. The current share price of US$133.06 reflects a modest 5.2% discount to the consensus analyst price target of US$140.41, suggesting a perception of fair valuation compared to expected earnings growth and projected revenue increases. Insights from our recent valuation report point to the potential undervaluation of Abbott Laboratories shares in the market. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:ABT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
12 hours ago
- Business Wire
Australia's SkyJuice Foundation Wins Top Global Prize for Emergency Water Innovation
DUBAI, United Arab Emirates--(BUSINESS WIRE)--SkyJuice Foundation from Australia has been awarded the Innovative Crisis Solutions Award during the fourth cycle of the Mohammed bin Rashid Al Maktoum Global Water Award. The foundation was honoured for its SkyHydrant Emergency Safe Water Solution, a rapid-response water treatment system providing potable water in humanitarian crises and disaster zones. Supervised by the UAE Water Aid Foundation (Suqia UAE), under the umbrella of the Mohammed bin Rashid Al Maktoum Global Initiatives, the award carries a total prize pool of USD 1 million and supports breakthrough technologies that address global water challenges through sustainability and resilience. The GEM Rapid Response Pack, SkyHydrant's flagship emergency solution, can deliver up to 10,000 litres of safe drinking water per day using passive ultrafiltration. Requiring no power, chemicals or technical expertise, the system can be assembled on-site within two to three hours for rapid global deployment. Its patented 'Shake 'n Flush' cleaning system ensures a lifecycle of up to four years. Used by over 25 NGOs and deployed in 74 countries, SkyHydrant units have supported disaster-affected populations in places such as Turkey, Ukraine, Haiti, Lebanon, the Philippines and Myanmar. Designed for displaced communities of 500 to 1,000 people, the system treats water from non-saline sources like rivers, streams and swamps, effectively removing bacteria, viruses, turbidity, algae and coliforms. With capital costs between USD 1,500 and USD 3,000, the system offers a highly cost-effective solution, often less than 50 cents per person annually based on a daily consumption of 50 litres. Maintenance involves basic monthly membrane cleaning, and the entire unit can be redeployed as needed in other emergency settings. 'What we need are decentralised, low-cost, sustainable solutions based on nature and embracing biomimicry that are distributed to poor communities so they can own and operate them. The sooner we can provide everybody with safe drinking water – whether they be refugees, displaced people or people in developing countries – the closer we move towards better equality throughout the world. Receiving this award is a great accolade for all the people that work within the foundation. It validates the meaningfulness of our work, highlights that it is appreciated and also helps to introduce us to other partners,' said Rhett Butler, Chairman and Founder of SkyJuice Foundation.
